Literature DB >> 25754095

Insulin secretion abnormalities in exocrine pancreatic sufficient cystic fibrosis patients.

Jamie L Wooldridge1, Rhonda D Szczesniak2, Matthew C Fenchel2, Deborah A Elder3.   

Abstract

BACKGROUND: The aim of this study is to assess insulin secretion in pediatric cystic fibrosis (CF) patients with exocrine pancreatic sufficiency.
METHODS: Glucose and insulin responses during an oral glucose tolerance test (OGTT) were measured in 146 CF patients. Patients were divided into exocrine sufficient (CF-PS) and insufficient (CF-PI) groups based on pancreatic enzyme usage and fecal elastase. A reference group included healthy, non-diabetic subjects.
RESULTS: All CF groups showed reduced insulin secretion as measured by insulinogenic index. The CF-PS patients had normal glucose tolerance. There was a direct correlation between BMI z-score and insulin area under the curve.
CONCLUSION: Patients with CF have reduced insulin secretion during an OGTT regardless of exocrine pancreatic status. The abnormal insulin secretion in all CF patients may predispose them for glucose intolerance, particularly when challenged by inflammation, infection, or nutritional deficiency. In addition, the diminished insulin secretion may contribute to increased catabolism. Lastly, the CF-related diabetes (CFRD) screening guidelines should be followed by all CF patients regardless of pancreatic status.
Copyright © 2015 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anabolism; Hyperglycemia; Insulin deficiency; Insulin-secreting cells; Pancreatic cystic fibrosis

Mesh:

Substances:

Year:  2015        PMID: 25754095      PMCID: PMC4561041          DOI: 10.1016/j.jcf.2015.02.009

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  28 in total

1.  Standardisation of spirometry.

Authors:  M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger
Journal:  Eur Respir J       Date:  2005-08       Impact factor: 16.671

2.  Standards of medical care in diabetes--2007.

Authors: 
Journal:  Diabetes Care       Date:  2007-01       Impact factor: 19.112

3.  Spirometric reference values from a sample of the general U.S. population.

Authors:  J L Hankinson; J R Odencrantz; K B Fedan
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

4.  Cystic fibrosis transmembrane conductance regulator deficiency exacerbates islet cell dysfunction after beta-cell injury.

Authors:  Michael S Stalvey; Christian Muller; Desmond A Schatz; Clive H Wasserfall; Martha L Campbell-Thompson; Douglas W Theriaque; Terence R Flotte; Mark A Atkinson
Journal:  Diabetes       Date:  2006-07       Impact factor: 9.461

5.  Proteolysis associated with insulin resistance in cystic fibrosis.

Authors:  D S Hardin; A LeBlanc; S Lukenbaugh; L Para; D K Seilheimer
Journal:  Pediatrics       Date:  1998-03       Impact factor: 7.124

6.  Diabetes mellitus in cystic fibrosis is characterized by islet amyloidosis.

Authors:  M Couce; T D O'Brien; A Moran; P C Roche; P C Butler
Journal:  J Clin Endocrinol Metab       Date:  1996-03       Impact factor: 5.958

7.  Glucose homeostasis and genotype-phenotype interplay in cystic fibrosis patients with CFTR gene deltaF508 mutation.

Authors:  Vanessa Preumont; Michel P Hermans; Patrick Lebecque; Martin Buysschaert
Journal:  Diabetes Care       Date:  2007-03-02       Impact factor: 19.112

8.  Beta-cell function, insulin sensitivity, and glucose tolerance in obese diabetic and nondiabetic adolescents and young adults.

Authors:  Deborah A Elder; Ronald L Prigeon; R Paul Wadwa; Lawrence M Dolan; David A D'Alessio
Journal:  J Clin Endocrinol Metab       Date:  2005-11-01       Impact factor: 5.958

9.  Glucose tolerance, insulin secretion, and insulin sensitivity in children and adolescents with cystic fibrosis and no prior history of diabetes.

Authors:  Deborah A Elder; Jamie L Wooldridge; Lawrence M Dolan; David A D'Alessio
Journal:  J Pediatr       Date:  2007-09-17       Impact factor: 4.406

10.  Expression and localization of cystic fibrosis transmembrane conductance regulator in the rat endocrine pancreas.

Authors:  Alain Boom; Pascale Lybaert; Jean-François Pollet; Paul Jacobs; Hassan Jijakli; Philippe E Golstein; Abdullah Sener; Willy J Malaisse; Renaud Beauwens
Journal:  Endocrine       Date:  2007-11-27       Impact factor: 3.633

View more
  12 in total

1.  Cystic fibrosis-related diabetes is caused by islet loss and inflammation.

Authors:  Nathaniel J Hart; Radhika Aramandla; Gregory Poffenberger; Cody Fayolle; Ariel H Thames; Austin Bautista; Aliya F Spigelman; Jenny Aurielle B Babon; Megan E DeNicola; Prasanna K Dadi; William S Bush; Appakalai N Balamurugan; Marcela Brissova; Chunhua Dai; Nripesh Prasad; Rita Bottino; David A Jacobson; Mitchell L Drumm; Sally C Kent; Patrick E MacDonald; Alvin C Powers
Journal:  JCI Insight       Date:  2018-04-19

Review 2.  The effect of cystic fibrosis transmembrane conductance regulator modulators on impaired glucose tolerance and cystic fibrosis related diabetes.

Authors:  Sana Hasan; Mohammad Salman Khan; M Cecilia Lansang
Journal:  J Clin Transl Endocrinol       Date:  2022-06-14

3.  Cystic Fibrosis Related Diabetes: a Unique Challenge in Diabetes Care.

Authors:  Marina Litvin; Schola Nwachukwu
Journal:  Mo Med       Date:  2016 Sep-Oct

4.  Structural abnormalities in islets from very young children with cystic fibrosis may contribute to cystic fibrosis-related diabetes.

Authors:  Marika Bogdani; Scott M Blackman; Cecilia Ridaura; Jean-Pierre Bellocq; Alvin C Powers; Lydia Aguilar-Bryan
Journal:  Sci Rep       Date:  2017-12-08       Impact factor: 4.379

Review 5.  Evolving Mechanistic Views and Emerging Therapeutic Strategies for Cystic Fibrosis-Related Diabetes.

Authors:  John C Yoon
Journal:  J Endocr Soc       Date:  2017-10-30

Review 6.  Cystic Fibrosis-Related Diabetes: Pathophysiology and Therapeutic Challenges.

Authors:  Ryan Kelsey; Fiona N Manderson Koivula; Neville H McClenaghan; Catriona Kelly
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2019-05-28

7.  Heterogeneous expression of CFTR in insulin-secreting β-cells of the normal human islet.

Authors:  Mauricio Di Fulvio; Marika Bogdani; Myrian Velasco; Timothy S McMillen; Cecilia Ridaura; Lisa Kelly; Mohammed M Almutairi; Shams Kursan; Abu A Sajib; Marcia Hiriart; Lydia Aguilar-Bryan
Journal:  PLoS One       Date:  2020-12-02       Impact factor: 3.240

Review 8.  Islet Function in the Pathogenesis of Cystic Fibrosis-Related Diabetes Mellitus.

Authors:  Efraim Westholm; Anna Wendt; Lena Eliasson
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2021-07-13

9.  The ΔF508 Mutation in the Cystic Fibrosis Transmembrane Conductance Regulator Is Associated With Progressive Insulin Resistance and Decreased Functional β-Cell Mass in Mice.

Authors:  Ghislaine Fontés; Julien Ghislain; Isma Benterki; Bader Zarrouki; Dominique Trudel; Yves Berthiaume; Vincent Poitout
Journal:  Diabetes       Date:  2015-08-17       Impact factor: 9.461

10.  Are low levels of serum bicarbonate associated with risk of progressing to impaired fasting glucose/diabetes? A single-centre prospective cohort study in Beijing, China.

Authors:  Sen Li; Ying-Ying Wang; Jing Cui; Dong-Ning Chen; Yu Li; Zhong Xin; Rong-Rong Xie; Xi Cao; Jing Lu; Fang-Yuan Yang; Jin-Kui Yang
Journal:  BMJ Open       Date:  2018-07-23       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.